moxifloxacin has been researched along with HIV Infections in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (11.76) | 29.6817 |
| 2010's | 8 (47.06) | 24.3611 |
| 2020's | 7 (41.18) | 2.80 |
| Authors | Studies |
|---|---|
| Caceres, M; Devinsky, O; Huddlestone, JR; Kasserra, C; Medlock, M; Morrison, R; O'Mara, E; Soni, P; Wan, Y | 1 |
| Badal-Faesen, S; Bryant, K; Campbell, K; Chaisson, RE; Dawson, R; Dooley, KE; Dorman, SE; Fletcher, CV; Johnson, JL; Kurbatova, EV; Lalloo, U; Martinson, N; Mayanja, H; Mohapi, L; Nahid, P; Pettit, A; Pham, M; Phillips, PPJ; Podany, AT; Samaneka, W; Scott, N; Sizemore, E; Swindells, S; Vernon, A; Whitworth, WC | 1 |
| Bryant, K; Chaisson, RE; Dawson, R; Dooley, KE; Dorman, SE; Johnson, JL; Kurbatova, E; Lalloo, UG; Mohapi, L; Muzanyi, G; Nahid, P; Pettit, AC; Phillips, PPJ; Podany, AT; Samaneka, W; Sanne, I; Savic, RM; Scott, N; Sizemore, E; Swindells, S; Vernon, A; Waja, Z | 1 |
| Haerting, M; Herpertz, G; Radke, O | 1 |
| Cai, DH; Fang, XL; Wang, J | 1 |
| Bozeman, L; Burman, WJ; Chaisson, RE; Chang, KC; Chen, M; Cotton, M; Dooley, KE; Dorman, SE; Engle, M; Feng, PJ; Fletcher, CV; Goldberg, SV; Ha, P; Heilig, CM; Johnson, JL; Kurbatova, EV; Lessem, E; Metchock, B; Miro, JM; Nahid, P; Nhung, NV; Pettit, AC; Phillips, PPJ; Podany, AT; Purfield, AE; Robergeau, K; Samaneka, W; Scott, NA; Sizemore, E; Swindells, S; Vernon, A; Weiner, M | 1 |
| Cao, Y; Xu, S; Zhou, M; Zhu, F | 1 |
| Draper, HR; Fourie, B; Garcia-Prats, AJ; Hesseling, AC; Nielsen, J; Radtke, KK; Savic, RM; Schaaf, HS; Solans, BP; Thee, S; van der Laan, LE; Wiesner, L; Winckler, JL | 1 |
| Clarke, S; Houlihan, L; Lyons, F; McFaul, K; Rowley, D | 1 |
| Christinet, V; Comte, E; du Cros, P; Ford, N; O'Brien, DP | 1 |
| Taylor-Robinson, D | 1 |
| Castel, S; Draper, HR; Garcia-Prats, AJ; Hesseling, AC; McIlleron, HM; Schaaf, HS; Thee, S; Wiesner, L | 1 |
| Ahuja, SD; Proops, DC; Trieu, L | 1 |
| Adamson, J; Chirehwa, M; Denti, P; Essack, S; Govender, K; Kimba-Phongi, E; McIlleron, H; Naidoo, A; Naidoo, K; Padayatchi, N; Yende-Zuma, N | 1 |
| Bonora, S; Calcagno, A; Di Perri, G; Lucchini, A; Mondo, A; Trentini, L | 1 |
| Arnaud, P; Berdot, S; Bouvet, E; Diamantis, S; Dombret, MC; Papy, E; Rioux, C; Ruimy, R | 1 |
| Bassetti, M; DI Biagio, A; Righi, E; Rosso, R; Tosi, C; Viscoli, C | 1 |
1 review(s) available for moxifloxacin and HIV Infections
| Article | Year |
|---|---|
Moxifloxacin for Buruli ulcer/HIV coinfected patients: kill two birds with one stone?
Topics: Anti-Bacterial Agents; Anti-Retroviral Agents; Aza Compounds; Buruli Ulcer; Drug Interactions; Fluoroquinolones; HIV Infections; Humans; Moxifloxacin; Quinolines | 2013 |
5 trial(s) available for moxifloxacin and HIV Infections
| Article | Year |
|---|---|
Effect of vicriviroc on the QT/corrected QT interval and central nervous system in healthy subjects.
Topics: Adolescent; Adult; Anti-HIV Agents; Arrhythmias, Cardiac; CCR5 Receptor Antagonists; Central Nervous System; Electrocardiography; Electroencephalography; Female; Heart; HIV Infections; Humans; Male; Middle Aged; Piperazines; Pyrimidines; Ritonavir; Young Adult | 2010 |
Efavirenz Pharmacokinetics and Human Immunodeficiency Virus Type 1 (HIV-1) Viral Suppression Among Patients Receiving Tuberculosis Treatment Containing Daily High-Dose Rifapentine.
Topics: Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Cyclopropanes; HIV Infections; HIV-1; Humans; Moxifloxacin; Rifampin; Tuberculosis | 2022 |
Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349).
Topics: Antitubercular Agents; Drug Therapy, Combination; HIV; HIV Infections; Humans; Isoniazid; Moxifloxacin; Rifampin; Tuberculosis; Tuberculosis, Pulmonary | 2023 |
High-dose rifapentine with or without moxifloxacin for shortening treatment of pulmonary tuberculosis: Study protocol for TBTC study 31/ACTG A5349 phase 3 clinical trial.
Topics: Adolescent; Adult; Antitubercular Agents; Directly Observed Therapy; Drug Administration Schedule; Drug Therapy, Combination; Equivalence Trials as Topic; Ethambutol; Female; HIV Infections; Humans; Male; Middle Aged; Moxifloxacin; Rifampin; Tuberculosis, Pulmonary; Young Adult | 2020 |
Effect of rifampicin and efavirenz on moxifloxacin concentrations when co-administered in patients with drug-susceptible TB.
Topics: Adult; Africa; Alkynes; Anti-HIV Agents; Antibiotics, Antitubercular; Benzoxazines; Coinfection; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; Female; Fluoroquinolones; HIV Infections; Humans; Male; Moxifloxacin; Reverse Transcriptase Inhibitors; Rifampin; Tuberculosis, Pulmonary | 2017 |
11 other study(ies) available for moxifloxacin and HIV Infections
| Article | Year |
|---|---|
[Case report about an initial diagnosis of HIV-infection in a young sailor through two AIDS-defining diseases with lethal progression].
Topics: Acquired Immunodeficiency Syndrome; Adult; Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Ganciclovir; HIV Infections; Humans; Meropenem; Military Personnel; Moxifloxacin; Pneumonia, Pneumocystis | 2022 |
Successful treatment of Talaromyces marneffei pneumonia in a HIV-negative renal transplantation recipient: A case report.
Topics: Antifungal Agents; HIV Infections; Humans; Kidney Transplantation; Moxifloxacin; Mycoses; Pneumonia; Tacrolimus; Talaromyces; Voriconazole | 2022 |
Co-infection of SARS-CoV-2 and HIV in a patient in Wuhan city, China.
Topics: Anti-HIV Agents; Betacoronavirus; China; Clinical Laboratory Techniques; Coinfection; Coronavirus Infections; COVID-19; COVID-19 Testing; Diabetes Mellitus, Type 2; Drug Combinations; gamma-Globulins; HIV; HIV Infections; Humans; Lopinavir; Male; Methylprednisolone; Middle Aged; Moxifloxacin; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2; Tomography, X-Ray Computed; Treatment Outcome | 2020 |
Moxifloxacin Pharmacokinetics, Cardiac Safety, and Dosing for the Treatment of Rifampicin-Resistant Tuberculosis in Children.
Topics: Adult; Child; Child, Preschool; Electrocardiography; Fluoroquinolones; HIV Infections; Humans; Moxifloxacin; Rifampin; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2022 |
A diagnostic dilemma: drug-induced aseptic meningitis in a 45-year-old HIV-positive man.
Topics: Anti-Bacterial Agents; Aza Compounds; Fluoroquinolones; HIV Infections; Humans; Male; Meningitis, Aseptic; Middle Aged; Moxifloxacin; Quinolines; Treatment Outcome | 2014 |
Diagnosis and antimicrobial treatment of Mycoplasma genitalium infection: sobering thoughts.
Topics: Anti-Bacterial Agents; Azithromycin; Coinfection; Doxycycline; Drug Resistance, Bacterial; Female; Fluoroquinolones; HIV Infections; Humans; Male; Moxifloxacin; Mycoplasma genitalium; Mycoplasma Infections; Urethritis | 2014 |
Pharmacokinetics and safety of moxifloxacin in children with multidrug-resistant tuberculosis.
Topics: Adolescent; Antibiotics, Antitubercular; Area Under Curve; Child; Drug Tolerance; Female; Fluoroquinolones; Half-Life; HIV Infections; Humans; Male; Moxifloxacin; Prospective Studies; South Africa; Tuberculosis, Multidrug-Resistant | 2015 |
Moxifloxacin Prophylaxis against MDR TB, New York, New York, USA.
Topics: Antibiotic Prophylaxis; Antitubercular Agents; Coinfection; Fluoroquinolones; Follow-Up Studies; HIV Infections; Humans; Moxifloxacin; Mycobacterium tuberculosis; New York City; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2015 |
Moxifloxacin for the treatment of HIV-associated tuberculosis in patients with contraindications or intolerance to rifamycins.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Aza Compounds; Contraindications; Drug Resistance, Bacterial; Fluoroquinolones; HIV Infections; Humans; Male; Middle Aged; Moxifloxacin; Mycobacterium tuberculosis; Quinolines; Rifamycins; Treatment Outcome; Tuberculosis | 2008 |
[Use of moxifloxacin in tuberculosis regimen in a French teaching hospital].
Topics: Adult; Aged; Antitubercular Agents; Aza Compounds; Comorbidity; Drug Prescriptions; Drug Therapy, Combination; Drug Utilization; Female; Fluoroquinolones; France; HIV Infections; Hospitals, University; Humans; Male; Middle Aged; Moxifloxacin; Quinolines; Recurrence; Retrospective Studies; Tuberculosis; Young Adult | 2010 |
Moxifloxacin in the treatment of hospitalised community acquired pneumonia in HIV-infected subjects.
Topics: Adult; Aza Compounds; Community-Acquired Infections; Female; Fluoroquinolones; HIV Infections; Hospitalization; Humans; Male; Middle Aged; Moxifloxacin; Pneumonia, Bacterial; Quinolines | 2007 |